Subscribe

Paul Wotton, PhD

Chief Executive Officer, Obsidian Therapeutics

Articles by Paul Wotton, PhD

Latest Updated Articles

Trending on CGTlive®

Sarepta Therapeutics’ Limb-Girdle Muscular Dystrophy Gene Therapy SRP-9003 Produces “Robust Expression” of β-SG in Phase 3 Trial

AAVantgarde’s Stargardt Gene Therapy AAVB-039 Garners FDA Orphan Drug Designation, Cleared for Trial in UK

© 2025 MJH Life Sciences^®

All rights reserved.